Compare Adaptive Biotechnologies Corp (ADPT) vs BigBearai Holdings Inc (BBAI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs BigBearai Holdings Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.06 (market cap $3.33B), while BigBearai Holdings Inc trades at $3.3 (market cap $1.64B). The key difference: Adaptive Biotechnologies Corp is far larger — about 2× BigBearai Holdings Inc's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, BigBearai Holdings Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | BBAI | |
|---|---|---|
Market Cap | $3.33B | $1.64B |
Sector | Health | Technology |
52-Week High | $22.37 | $8.91 |
52-Week Low | $10.24 | $3.05 |
Enterprise Value | $3.19B | $1.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
BBAI trades at $3.58, up 1.42% today, but technical indicators signal a bearish trend with strong selling pressure. The company reported a net loss of $293.91 million in 2025, with negative profit margins and cash flow from operations. Recent news highlights expansion into AI-powered airport security and government contracts, though high SG&A expenses and persistent losses remain concerns. Analyst consensus is cautious, with 75% hold ratings.
The outlook is challenged by ongoing losses and rich valuation, but growth in AI contracts and backlog offers potential upside. Key risks include execution on profitability, competitive pressures, and reliance on government spending. Investors should weigh the high-risk, high-reward profile amid volatile market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About BigBearai Holdings Inc
BigBearai Holdings Inc is a specialized provider of AI-driven decision intelligence solutions, primarily serving the U.S. defense, intelligence, and national security communities. It operationalizes complex data into actionable insights through its core modules—Observe, Orient, and Dominate—to support mission-critical operations and logistics.
Read more on BBAI →
